Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

With Zydus Lifesciences Limited's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.00000
forwardPE 19.00364
debtToEquity 0.78900
earningsGrowth 0.30400
revenueGrowth 0.17000
grossMargins 0.71152
operatingMargins 0.18523
trailingEps 44.98000
forwardEps 0.00000

Zydus Lifesciences Limited's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Positive earnings and revenue growth for ZYDUSLIFE point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Over time, Zydus Lifesciences Limited's price projections have been gradually lowered, signaling declining confidence in the company's future outlook. The downward revisions suggest analysts are becoming more cautious about Zydus Lifesciences Limited's potential for growth.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


5 sales transactions of ZYDUSLIFE were conducted, with market price at 999.05.There were no sell transactions during the given period.The recent trend of more purchases than sales at ZYDUSLIFE's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Analysts have maintained a buy bias for Zydus Lifesciences Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Zydus Lifesciences Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.